MPNs

Hany Elmariah, MD, discusses dose-limiting toxicities of fedratinib in a phase 1 study exploring the drug in patients with myeloproliferative neoplasms after HCT.

Akriti Jain, MD, discussed how emerging data on non-ABL1 mutations is reshaping chronic myeloid leukemia management.

Douglas A. Tremblay, MD, discusses the long-term data supporting ropeginterferon alfa-2b-njft as treatment in patients with polycythemia vera.

The investigational immunotherapy bexmarilimab has been granted orphan drug designation from the FDA for patients with myelodysplastic syndromes.

Rusfertide outperformed placebo in polycythemia vera, meeting all primary and secondary end points in the phase 3 VERIFY study.

The first patient with myelodysplastic syndrome has received iadademstat plus azacitidine in a phase 1 trial at the Medical College of Wisconsin.

Hany Elmariah, MD, discussed the safety profile of fedratinib and its evolving role in the post-transplant setting for patients with myeloproliferative neoplasms.

During a Case-Based Roundtable® event, Jay Yang, MD, discussed the trial comparing luspatercept with ESA in myelodysplastic syndrome.

During a live event, Andrew Kuykendall, MD, discussed management of anemia before and during use of JAK inhibitor for myelofibrosis in the second of 2 articles.

During a Case-Based Roundtable® event, Andrew Kuykendall, MD, and participants discussed the the importance of early intervention and consideration of anemia with JAK inhibitor therapy for patients with myelofibrosis in the first article of a 2-part series.

In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.

R289 has gained orphan drug status from the FDA for the treatment of patients with myelodysplastic syndromes.

The SURPASS-ET trial demonstrated ropeginterferon alfa-2b's superior efficacy over anagrelide, achieving higher durable response rates and greater reduction in JAK2 allele burden among patients with essential thrombocythemia.

During a Case-Based Roundtable® event, Andrew Kuykendall, MD, discussed treatment for a 68-year-old patient with intermediate-1 risk myelofibrosis and mild anemia.

Solly Chedid, MD, discussed luspatercept and its role in boosting quality of life for patients with myelodysplastic syndrome.

Frontline tyrosine kinase inhibitors are well-established for chronic myelogenous leukemia, but some patients experience inadequate response or adverse events, highlighting the need for novel therapies.

Positive topline data from a phase 2 trial show HT-6184, an allosteric NEK7/NLRP3 inflammasome inhibitor, improves hematologic response in lower-risk MDS.

Erythropoietin stimulating agents and/or luspatercept showed positive clinical efficacy and safety in patients with VEXAS syndrome, with or without MDS.

Findings from the BOREAS study showed that navtemadlin as a monotherapy led to safety and efficacy in patients with myelofibrosis who were relapsed or refractory to JAK inhibitors.

Updated 96-week data from the ASC4FIRST trial show asciminib significantly outperforms standard TKIs in major molecular response for patients with CML.

Cladribine plus venetoclax improved complete response and CR with incomplete count recovery rates in MRD-negative patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.

Selinexor with ruxolitinib demonstrated encouraging efficacy with a manageable safety profile in patients with myelofibrosis who were previously treated with ruxolitinib.

Venetoclax with hypomethylating agents produced better responses than HMAs alone in adult patients with myelodysplastic syndrome.

In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.

Olverembatinib demonstrates potential as a safe, effective second-line therapy for chronic-phase CML after resistance to second-generation TKIs, according to ChiCTR2200061655 trial data.